The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
Open accessAbstract
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides. Early clinical studies evaluating the safety and efficacy of Lu PSMA therapy have demonstrated promising results with a significant proportion of men with metastatic prostate cancer, who have already failed other therapies, responding clinically to Lu PSMA. This review discusses the practical issues of administering Lu PSMA, and gives an overview of the findings from currently published trials in regards to treatment response rates, expected toxicities and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Benešová, M., Schäfer, M., Bauder-Wüst, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 612
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Wright, G. L., Haley, C., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 591
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525
Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 458
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Afshar-Oromieh, A., Hetzheim, H., Kratochwil, C., Benesova, M., Eder, M., Neels, O. C., Eisenhut, M., Kübler, W., Holland-Letz, T., Giesel, F. L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161299 · Cited by 427
Tagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
Ljungberg, M., Celler, A., Konijnenberg, M. W., Eckerman, K. F., Dewaraja, Y. K., & Sjögreen-Gleisner, K. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.159012 · Cited by 369
Zechmann, C. M., Afshar-Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B., Joyal, J., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2713-y · Cited by 358
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322
Ahmadzadehfar, H., Rahbar, K., Kürpig, S., Bögemann, M., Claesener, M., Eppard, E., Gärtner, F., Rogenhofer, S., Schäfers, M., & Essler, M. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0114-2 · Cited by 293
Ahmadzadehfar, H., Eppard, E., Kürpig, S., Fimmers, R., Yordanova, A., Schlenkhoff, C. D., Gärtner, F., Rogenhofer, S., & Essler, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7245 · Cited by 282
Haffner, M. C., Kronberger, I. E., Ross, J. S., Sheehan, C. E., Zitt, M., Mühlmann, G., Öfner, D., Zelger, B., Ensinger, C., Yang, X. J., et al. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.06.003 · Cited by 236
Is prostate-specific membrane antigen a multifunctional protein?
Rajasekaran, A. K., Anilkumar, G., & Christiansen, J. J. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00506.2004 · Cited by 232
Rahbar, K., Schmidt, M., Heinzel, A., Eppard, E., Bode, A., Yordanova, A., Claesener, M., & Ahmadzadehfar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173757 · Cited by 213
Kabasakal, L., AbuQbeitah, M., Aygün, A., Yeyin, N., Ocak, M., Demirci, E., & Toklu, T. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3125-3 · Cited by 208
Garkavij, M., Nickel, M., Sjögreen‐Gleisner, K., Ljungberg, M., Ohlsson, T., Wingårdh, K., Strand, S., & Tennvall, J. (2010) · Cancer · doi:10.1002/cncr.24796 · Cited by 205
[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer
Kratochwil, C., Giesel, F. L., Eder, M., Afshar-Oromieh, A., Benešová, M., Mier, W., Kopka, K., & Haberkorn, U. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2978-1 · Cited by 196
Rahbar, K., Bode, A., Weckesser, M., Avramovic, N., Claesener, M., Stegger, L., & Bögemann, M. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001240 · Cited by 187
Heck, M. M., Retz, M., D'Alessandria, C., Rauscher, I., Scheidhauer, K., Maurer, T., Storz, E., Janssen, F., Schottelius, M., Wester, H.-J., et al. (2016) · Journal of Urology · doi:10.1016/j.juro.2016.02.2969 · Cited by 187
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Sandström, M., Garske, U., Granberg, D., Sundin, A., & Lundqvist, H. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1216-8 · Cited by 182
Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3481-7 · Cited by 147
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J. R., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., & Bander, N. H. (2010) · Cancer · doi:10.1002/cncr.24795 · Cited by 144
Ferdinandus, J., Eppard, E., Gaertner, F. C., Kürpig, S., Fimmers, R., Yordanova, A., Hauser, S., Feldmann, G., Essler, M., & Ahmadzadehfar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178228 · Cited by 132
Fendler, W. P., Kratochwil, C., Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Schmidt, M. C., Pfestroff, A., Lützen, U., Prasad, V., Heinzel, A., et al. (2016) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0037-1616480 · Cited by 113
Oudard, S. M. (2011) · Future Oncology · doi:10.2217/fon.11.23 · Cited by 105
Vallabhajosula, S., Nikolopoulou, A., Jhanwar, Y. S., Kaur, G., Tagawa, S. T., Nanus, D. M., Bander, N. H., & Goldsmith, S. J. (2015) · Current Radiopharmaceuticals · doi:10.2174/1874471008666150313114005 · Cited by 83
Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy.
Cremonesi, M., Ferrari, M., Dia, A. D., Botta, F., Cicco, C. D., Bodei, L., & Paganelli, G. (2011) · PubMed · Cited by 56
Demır, M., Abuqbeitah, M., Uslu, L., et al. (2016) · Journal of Radiological Protection · doi:10.1088/0952-4746/36/2/269 · Cited by 56
Gorin, M. A., Rowe, S. P., Hooper, J. E., Kates, M. R., Hammers, H.-J., Szabó, Z. R., Pomper, M. G., & Allaf, M. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.019 · Cited by 49
Tagawa, S. T., Akhtar, N. H., Nikolopoulou, A., Kaur, G., Robinson, B. D., Kahn, R., Vallabhajosula, S., Goldsmith, S. J., Nanus, D. M., & Bander, N. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00214 · Cited by 34
Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium
Heck, M. M., Retz, M. M., Tauber, R., Knorr, K., Kratochwil, C., & Eiber, M. (2016) · Der Urologe · doi:10.1007/s00120-016-0274-3 · Cited by 34
Rhee, H., Ng, K. L., Tse, B. W.-C., Yeh, M.-C., Russell, P. J., Nelson, C. C., Thomas, P. A., Samaratunga, H., Vela, I., Gobe, G. C., et al. (2016) · Pathology · doi:10.1016/j.pathol.2016.05.011 · Cited by 33
Cited by
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Hennrich, U., & Eder, M. (2022) · Pharmaceuticals · doi:10.3390/ph15101292 · Cited by 318
Metadata
- Authors
- Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J.
- Venue
- Journal of Medical Radiation Sciences
- Publisher
- Wiley
- Published
- 2017-03
- Volume
- 64
- Issue
- 1
- Pages
- 52-60
- ISSN
- 2051-3895 (ISSN-L)
- 2051-3909
- OpenAlex
- W2596023559
- Cited by
- 305
- References
- 36
- FWCI
- 20.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.